This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safusidenib Phase 2 Study in IDH1 Mutant Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05303519
Recruitment Status : Recruiting
First Posted : March 31, 2022
Last Update Posted : November 14, 2023
Sponsor:
Information provided by (Responsible Party):
AnHeart Therapeutics Inc.

Tracking Information
First Submitted Date  ICMJE March 13, 2022
First Posted Date  ICMJE March 31, 2022
Last Update Posted Date November 14, 2023
Actual Study Start Date  ICMJE June 5, 2023
Estimated Primary Completion Date March 31, 2027   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 21, 2022)
  • part1: Incidence of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: From participants sign ICF to 30 days after last dose,average 2 years ]
    calculate Percentage and numbers of participants with adverse events (AEs) and serious adverse events (SAEs) assessed by CTCAE 5.0
  • part2: ORR by the IRC [ Time Frame: from drug treatment to 2 years ]
    ORR (defined as the proportion of participants with the best overall confirmed response of CR or PR[for RANO LGG] according to the appropriate tumor response criteria) as assessed by the IRC
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 23, 2023)
  • Part 1 Stage 1: Cmax of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Peak Plasma Concentration (Cmax)
  • Part 1 Stage 1: Tmax of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    the time for safusidenib to reach Cmax
  • Part 1 Stage 1: AUC8h of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 8 hours
  • Part 1 Stage 1: AUC12h of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 12 hours
  • Part 1 Stage 1: AUC24h [QD only] of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 24h hours for 500mg qd cohort
  • Part 1 Stage 1: Ctrough of safusidenib [ Time Frame: on Days 2, 3, 4, 6, 8, 9 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 6 and 8 ]
    Lowest plasma concentration reached after AB-218 administration
  • Part 1 Stage 2: Cmax of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Peak Plasma Concentration (Cmax)
  • Part 1 Stage 2: Tmax of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    the time for AB-218 to reach Cmax
  • Part 1 Stage 2: AUC6h of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 6 hours
  • Part 1 Stage 2: Ctrough of safusidenib [ Time Frame: on Days 4, 8 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 8 ]
    Lowest plasma concentration reached after AB-218 administration
  • Part 1: ORR assessed by the investigator [ Time Frame: from drug treatment to 2 years ]
    ORR (defined as the proportion of participants with the best overall confirmed response of CR or PR [for RANO LGG] according to the appropriate tumor response criteria) as assessed by the Investigator
  • Part 1: DOR assessed by the Investigator [ Time Frame: from drug treatment to 2 years ]
    Duration of response (DOR, defined as the time from the first date of objective response [CR or PR, to the first documented date of disease progression per RANO or RANO LGG or the date of death due to any cause, whichever occurs first) as assessed by the Investigator
  • Part 1: DCR assessed by the Investigator [ Time Frame: from drug treatment to 2 years ]
    Disease control rate (DCR, defined as the proportion of patients with a best overall response of CR, PR, stable disease, or MR [for RANO LGG], per RANO or RANO LGG) as assessed by the Investigator
  • Part 1: PFS assessed by the Investigator [ Time Frame: from drug treatment to 2 years ]
    Progression free survival (PFS, defined as the time from first dose of AB 218 until the date of disease progression per RANO or RANO LGG or death [by any cause in the absence of progression]) as assessed by the Investigator
  • Part2: ORR, per RANO or RANO LGG, as applicable, by the Investigator [ Time Frame: from drug treatment to 2 years ]
    ORR (defined as the proportion of participants with the best overall confirmed response of CR or PR[for RANO LGG] according to the appropriate tumor response criteria) as assessed by the Investigator
  • Part2: DOR assessed by the IRC and by the Investigator [ Time Frame: from drug treatment to 2 years ]
    DOR, defined as the time from the first date of objective response [CR or PR, to the first documented date of disease progression per RANO or RANO LGG or the date of death due to any cause, whichever occurs first) as assessed by the Investigator and IRC
  • Part2: DCR assessed by the IRC and by the Investigator [ Time Frame: from drug treatment to 2 years ]
    DCR, defined as the proportion of patients with a best overall response of CR, PR, stable disease, or MR [for RANO LGG], per RANO or RANO LGG) as assessed by the Investigator and IRC
  • Part2: PFS assessed by the IRC and by the Investigator [ Time Frame: from drug treatment to 2 years ]
    PFS, defined as the time from first dose of AB 218 until the date of disease progression per RANO or RANO LGG or death [by any cause in the absence of progression]) as assessed by the Investigator and IRC
  • Part2: Overall survival (OS) [ Time Frame: from first dose of safusidenib to death ]
    OS: defined as the time from first dose of safusidenib until the date of death.
  • Part2: Incidence of AEs and SAEs [ Time Frame: From participants sign ICF to 30 days after last dose, average 2 years ]
    Percentage and numbers of participants with adverse events (AEs) and serious adverse events (SAEs) assessed by CTCAE 5.0
  • Part2: Cmax of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Peak Plasma Concentration (Cmax)
  • Part2: Tmax of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    the time for safusidenib to reach Cmax
  • Part2: AUC6h of safusidenib [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 6 hours
  • Part2: Ctrough of safusidenib [ Time Frame: on Days 4, 8 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 8 ]
    Lowest plasma concentration reached after safusidenib administration
Original Secondary Outcome Measures  ICMJE
 (submitted: March 21, 2022)
  • Part 1 Stage 1: Cmax of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Peak Plasma Concentration (Cmax)
  • Part 1 Stage 1: Tmax of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    the time for AB-218 to reach Cmax
  • Part 1 Stage 1: AUC8h of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 8 hours
  • Part 1 Stage 1: AUC12h of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 12 hours
  • Part 1 Stage 1: AUC24h [QD only] of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 24h hours for 500mg qd cohort
  • Part 1 Stage 1: Ctrough of AB-218 [ Time Frame: on Days 2, 3, 4, 6, 8, 9 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 6 and 8 ]
    Lowest plasma concentration reached after AB-218 administration
  • Part 1 Stage 2: Cmax of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Peak Plasma Concentration (Cmax)
  • Part 1 Stage 2: Tmax of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    the time for AB-218 to reach Cmax
  • Part 1 Stage 2: AUC6h of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 6 hours
  • Part 1 Stage 2: Ctrough of AB-218 [ Time Frame: on Days 4, 8 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 8 ]
    Lowest plasma concentration reached after AB-218 administration
  • Part 1: ORR assessed by the investigator [ Time Frame: from drug treatment to 2 years ]
    ORR (defined as the proportion of participants with the best overall confirmed response of CR or PR [for RANO LGG] according to the appropriate tumor response criteria) as assessed by the Investigator
  • Part 1: DOR assessed by the Investigator [ Time Frame: from drug treatment to 2 years ]
    Duration of response (DOR, defined as the time from the first date of objective response [CR or PR, to the first documented date of disease progression per RANO or RANO LGG or the date of death due to any cause, whichever occurs first) as assessed by the Investigator
  • Part 1: DCR assessed by the Investigator [ Time Frame: from drug treatment to 2 years ]
    Disease control rate (DCR, defined as the proportion of patients with a best overall response of CR, PR, stable disease, or MR [for RANO LGG], per RANO or RANO LGG) as assessed by the Investigator
  • Part 1: PFS assessed by the Investigator [ Time Frame: from drug treatment to 2 years ]
    Progression free survival (PFS, defined as the time from first dose of AB 218 until the date of disease progression per RANO or RANO LGG or death [by any cause in the absence of progression]) as assessed by the Investigator
  • Part2: ORR, per RANO or RANO LGG, as applicable, by the Investigator [ Time Frame: from drug treatment to 2 years ]
    ORR (defined as the proportion of participants with the best overall confirmed response of CR or PR[for RANO LGG] according to the appropriate tumor response criteria) as assessed by the Investigator
  • Part2: DOR assessed by the IRC and by the Investigator [ Time Frame: from drug treatment to 2 years ]
    DOR, defined as the time from the first date of objective response [CR or PR, to the first documented date of disease progression per RANO or RANO LGG or the date of death due to any cause, whichever occurs first) as assessed by the Investigator and IRC
  • Part2: DCR assessed by the IRC and by the Investigator [ Time Frame: from drug treatment to 2 years ]
    DCR, defined as the proportion of patients with a best overall response of CR, PR, stable disease, or MR [for RANO LGG], per RANO or RANO LGG) as assessed by the Investigator and IRC
  • Part2: PFS assessed by the IRC and by the Investigator [ Time Frame: from drug treatment to 2 years ]
    PFS, defined as the time from first dose of AB 218 until the date of disease progression per RANO or RANO LGG or death [by any cause in the absence of progression]) as assessed by the Investigator and IRC
  • Part2: Overall survival (OS) [ Time Frame: from first dose of AB-218 to death ]
    OS: defined as the time from first dose of AB-218 until the date of death.
  • Part2: Incidence of AEs and SAEs [ Time Frame: From participants sign ICF to 30 days after last dose, average 2 years ]
    Percentage and numbers of participants with adverse events (AEs) and serious adverse events (SAEs) assessed by CTCAE 5.0
  • Part2: Cmax of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Peak Plasma Concentration (Cmax)
  • Part2: Tmax of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    the time for AB-218 to reach Cmax
  • Part2: AUC6h of AB-218 [ Time Frame: on Cycle 1 Day 1 and Day 8 ]
    Area under the plasma concentration curve (AUC) from time 0 to 6 hours
  • Part2: Ctrough of AB-218 [ Time Frame: on Days 4, 8 of Cycle 1 and Day 1 of Cycles 2, 4, 6, and 8 ]
    Lowest plasma concentration reached after AB-218 administration
Current Other Pre-specified Outcome Measures
 (submitted: May 23, 2023)
  • for part 1 stage 2 surgical participants: Safusidenib concentrations in both plasma and tumor tissues [ Time Frame: in the 5th week after first safusidenib dose ]
    The concentration of safusidenib in tumor tissue samples collected at the time of tumor resection and plasma samples.
  • for part 1 stage 2 surgical participants: 2-hydroxyglutarate (2-HG) concentrations in the tumor tissue [ Time Frame: at the time of pre-treatment, and in the 5th week after first safusidenib dose ]
    The concentration of 2-HG in tumor tissue samples at the time of tumor resection posttreatment and in tumor tissue samples submitted pretreatment.
Original Other Pre-specified Outcome Measures
 (submitted: March 21, 2022)
  • for part 1 stage 2 surgical participants: AB-218 concentrations in both plasma and tumor tissues [ Time Frame: on the date of tumor resection, estimated in the 5th week after first AB-218 dose ]
    The concentration of AB-218 in tumor tissue samples collected at the time of tumor resection and plasma samples.
  • for part 1 stage 2 surgical participants: 2-hydroxyglutarate (2-HG) concentrations in the tumor tissue [ Time Frame: at the time of pre-treatment, and the time of tumor resection, estimated in the 5th week after first AB-218 dose ]
    The concentration of 2-HG in tumor tissue samples at the time of tumor resection posttreatment and in tumor tissue samples submitted pretreatment.
 
Descriptive Information
Brief Title  ICMJE Safusidenib Phase 2 Study in IDH1 Mutant Glioma
Official Title  ICMJE A Phase 2, Multicenter, Open Label, Two Parts Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Glioma
Brief Summary

This is a Phase 2, multicenter, open label, two parts, clinical study to evaluate the efficacy, safety, and PK of safusidenib. Patients with recurrent or progressive histologically confirmed IDH1 mutant WHO Grade 2/3 glioma10 outside Japan, will be enrolled in this study. It was divided into 2 parts.

Part 1: Up to 25 patients will be randomized 1:1:1:1:1 (5 patients per group) to receive one of the daily oral doses of safusidenib at 125 mg twice a day (BID), 250 mg BID, 500 mg once daily (QD), 375 mg BID, or 500 mg BID. The PK characteristics and safety and initial efficacy data will be assessed in Part 1.

Part 2: It is planned to open 2 glioma subtype cohorts: Grade 2 and Grade 3 glioma cohorts with 30 eligible patients enrolled in each cohort. Total 60 patients will be enrolled.

Part 2 is to evaluate the efficacy of safusidenib in the treatment of recurrent/progressive WHO CNS Grade 2 and grade 3 IDH1 mutant glioma.

Exploratory Surgery Cohort: This cohort will be conducted in parallel with Part 2, for explorative purpose once RP2D is decided. 5 patients with primarily enhancing lesions and other 5 with primarily non-enhancing lesions will be enrolled. Participants will receive oral safusidenib treatment continuously, with 28 days as a cycle, until disease progression, unacceptable toxicity, consent withdrawal, start of new anti-cancer therapy, investigator decision or death, upon whichever earlier.

Besides baseline, the anti-tumor response will be evaluated every 8 weeks following RANO or RANO-LGG criteria as applicable, until disease progression, consent withdrawal or death, upon whichever earlier.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Glioma
Intervention  ICMJE Drug: safusidenib
safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
Other Names:
  • DS-1001b
  • AB-218
Study Arms  ICMJE
  • Experimental: safusidenib 125mg bid
    safusidenib 125mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
    Intervention: Drug: safusidenib
  • Experimental: safusidenib 250mg bid
    safusidenib 250mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
    Intervention: Drug: safusidenib
  • Experimental: safusidenib 500mg qd
    safusidenib 500mg qd administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
    Intervention: Drug: safusidenib
  • Experimental: safusidenib 375mg bid
    safusidenib 375mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
    Intervention: Drug: safusidenib
  • Experimental: safusidenib 500mg bid
    safusidenib 500mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
    Intervention: Drug: safusidenib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 23, 2023)
95
Original Estimated Enrollment  ICMJE
 (submitted: March 21, 2022)
114
Estimated Study Completion Date  ICMJE July 31, 2027
Estimated Primary Completion Date March 31, 2027   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patient must be ≥ 18 years of age at the time of signing the informed consent form (ICF).

    Type of Patient and Disease Characteristics

  2. Patient must have histologically confirmed recurrent or progressive WHO Grade 2 glioma or Grade 3 glioma with IDH1 R132H or R132C mutation confirmed by immunohistochemistry or molecular genetic testing.
  3. Patient has available archived primary tumor biopsy or surgical specimens, or biopsies of recurrence of metastasis for retrospective IDH mutation confirmation and other genes testing to support the reconfirmation of Glioma WHO classification and explorative studies.
  4. The IDH mutation, and other applicable gene/molecular alterations (see Table 10-2) are determined by a validated assay as performed in Clinical Laboratory Improvement Amendments (CLIA)-certified/College of American Pathologists (CAP)-accredited or locally equivalent clinical laboratories. Prior clinical pathology report fulfilling the diagnosis criteria prior to screening with tumor samples collected is acceptable for patient enrollment in both Part 1 and Part 2.
  5. Patient has received no more than 2 prior therapies for disease recurrence/progression.
  6. Patient has disease recurrence or progression or cannot tolerate the most recent therapy.
  7. Patient must have a measurable lesion(s) as per the RANO-HGG criteria for primarily enhancing lesions or RANO-LGG criteria for primarily non-enhancing lesions. The lesion (s) must be visible on 2 or more axial slices and have perpendicular diameters of at least 10 × 10 mm. The definition of primarily enhancing lesions or primarily non-enhancing lesions is referred to Section 8.3.1.
  8. Patient must have life expectancy ≥ 3 months.
  9. Patient must have KPS score ≥ 60.
  10. Patient who has adequate organ functions as defined below:

    • AST and ALT: ≤ 2.5 × upper limit of normal (ULN)
    • Total bilirubin: ≤ 1.5 × ULN
    • Absolute neutrophil count: ≥ 1,500/μL
    • Platelet count: ≥ 100,000/μL (or ≥ 50,000/μL for prior temozolomide therapy)
    • Hemoglobin: ≥ 9.0 g/dL
    • Creatinine clearance (Cockcroft-Gault Formula) ≥ 60 mL/min An out-of-range laboratory test will be repeated up to 2 times before declaring a screen failure, and after expiration of screening window, patients will be re-screened.
  11. Recovery to Grade 1 or baseline from any toxicities due to prior therapies (except conditions such as alopecia, temozolomide-induced lymphopenia and irreversible changes associated with radiation therapy).
  12. Female patients who engage in heterosexual intercourse must be of non-childbearing potential, defined as either surgically sterile (e.g., hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), OR be postmenopausal with at least 1 year of amenorrhea, OR must agree to use a highly effective method of contraception from the beginning of Screening until at least 90 days after the last dose of safusidenib.

    Acceptable highly effective methods of contraception include:

    • Combined estrogen-progestin oral hormonal contraception associated with consistent inhibition of ovulation
    • Desogestrel-based progestin-only contraception associated with consistent inhibition of ovulation; this includes oral, injectable, and implantable methods
    • Intravaginal and transdermal hormone delivery methods
    • Intrauterine device (with or without hormone elution)
    • Bilateral tubal occlusion or ligation (must be documented)
    • Vasectomized partner (must be documented) or
    • Sexual abstinence (only when it is the usual and preferred lifestyle of the patient)

    Additional information for contraceptive measurements is provided in Appendix 4:

    Contraceptive and Barrier Guidance.

  13. Male patients should agree to use a condom when sexually active with a female partner of childbearing potential from Screening until at least 90 days after the last dose of safusidenib (or be surgically sterile [e.g., vasectomy with documentation]; or remain abstinent [when this is in line with the preferred and usual lifestyle]). Male patients should also agree to not donate sperm for the duration of the study and until at least 90 days after the last dose of safusidenib.
  14. Patient should be willing to provide written ICF.
  15. Ability to undergo the protocol-specified procedures, including blood tests and urinalysis.

Exclusion Criteria:

  1. Patients with history or complication of any of the following diseases within 6 months prior to the initial dose of safusidenib:

    • Myocardial infarction
    • Severe or unstable angina pectoris
    • Coronary or peripheral endovascular treatment
    • Heart failure
    • Cerebrovascular disorder including transient ischemic attack, stroke, central nervous system (CNS) bleeding.
  2. Uncontrolled active systemic fungal, bacterial, or other infection (despite appropriate antibiotics or other treatment).
  3. Gastrointestinal diseases that may interfere with oral ingestion of safusidenib or may affect absorption of safusidenib.
  4. Psychiatric disease or symptoms that may interfere with the patient's continuous participation in the study.
  5. Patients should be tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and those with active infection detected using either molecular or antigen tests in accordance with local testing guidelines will be excluded.
  6. Prior anti-cancer therapy, within the applicable periods shown below, before the start of the protocol treatment:

    • Systemic drug therapies: within 3 weeks (lomustine within 6 weeks)
    • Surgery: within 3 weeks
    • Radiation therapy: within 12 weeks
    • Investigational agents: within 5 half-lives for other investigational agents
  7. Patient did receive the prior therapy targeted to IDH1 mutation.
  8. Patients taking substrates of cytochrome CYP2C8, CYP2C9, and CYP3A4 (See Appendix 7) with narrow therapeutic window, should be excluded unless they can be transferred to other medications prior to enrolling. Patients taking sensitive CYP 2C8, 2C9 or 3A4 substrate medications may require dosage adjustment unless they can be transferred to other medications within ≥ 5 half-lives prior to dosing.
  9. Patients taking sensitive substrates of P-gp and BCRP transporters (See Appendix 7) should be excluded unless they can be transferred to other medications prior to enrolling.

    Patients taking sensitive substrates of P-gp and BCRP may require dosage adjustment unless they can be transferred to other medications within ≥ 5 half-lives prior to dosing.

  10. Advanced arrhythmia of Grade ≥ 2 per NCI-CTCAE v5.0, uncontrolled atrial fibrillation (any grade) and corrected QT interval by Fredericia's formula (QTcF) > 470 msec.
  11. Evidence of intraspinal dissemination or diffuse leptomeningeal disease by MRI.
  12. Positive test results for human immunodeficiency virus (HIV) antibody.
  13. Positive test results for hepatitis B surface (HBs) antigen and/or hepatitis C virus (HCV) antibody. Patients who have tested positive for hepatitis B core (HBc) antibody and/or HBs antibody, despite negative test results for HBs antigen, may be enrolled only if they have negative finding on quantitative hepatitis B virus (HBV) DNA assays and the Anti-HBV treatment is allowing during study period. Patients who are hepatitis C antibody positive will need to have a negative polymerase chain reaction (PCR) result before enrollment; those who are hepatitis C PCR positive will be excluded.
  14. Pregnant or breastfeeding female patient.
  15. Known hypersensitivity to safusidenib or to any drug with similar chemical structure or to any other excipient present in the pharmaceutical form of safusidenib.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Yan Li +1 212 466 6378 yli@anhearttherapeutics.com
Contact: Weiqing Wang +1 212 466 6378 wqwang@anhearttherapeutics.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05303519
Other Study ID Numbers  ICMJE AB-218-G203
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party AnHeart Therapeutics Inc.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE AnHeart Therapeutics Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account AnHeart Therapeutics Inc.
Verification Date November 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP